Skip to main content

How does nintedanib work?

NINTEDANIB IS A MULTI-TARGETED TYROSINE KINASE INHIBITOR THAT WORKS BY INHIBITING PATHWAYS INVOLVED IN THE PATHOGENESIS OF ILDs1-3

Explore the interactive MOA of nintedanib in 3D

See how common pathogenic pathways to pulmonary fibrosis are shared among different ILDs and how nintedanib works to inhibit key pathways involved in lung fibrosis. Select the chapters and labels to learn more. Click and drag to rotate and scroll to zoom.1,4-6

Launch interactive 3D experience
Lung

The MOA is based on preclinical data and provided for illustrative purposes only.

WATCH THE VIDEO TO LEARN HOW NINTEDANIB WORKS TO INHIBIT KEY PATHWAYS INVOLVED IN LUNG FIBROSIS1-3

Document ID: PC-SA-102502 | Expiry Date: 24/08/2026

NINTEDANIB IS A MULTITARGETED TYROSINE KINASE INHIBITOR (TKI) THAT INHIBITS PATHWAYS INVOLVED IN THE PATHOGENESIS OF ILDS1-3

How does nintedanib work?

On this page

Quicklinks
Multitargeted-TKI
Multitargeted TKI

Nintedanib is a multitargeted TKI that inhibits key pathways involved in lung fibrosis1

Nintedanib is not an
immunosuppressant.1

Intracellularly-Binds
Intracellularly Binds

Nintedanib binds intracellularly to key receptors to block downstream signaling cascades1,3

Proven-MOA
Proven MOA

Nintedanib has been shown to inhibit fibroblast proliferation, migration, and fibroblast-to-myofibroblast transformation1,3

NINTEDANIB BINDS INTRACELLULARLY TO KEY RECEPTORS TO BLOCK DOWNSTREAM SIGNALING CASCADES1,3

ofev-nintedanib-mechanism-of-action
ofev-nintedanib-mechanism-of-action

The MOA is based on preclinical data and provided for illustrative purposes only.1

NINTEDANIB AFFECTS THE UNDERLYING PATHWAYS INVOLVED IN FIBROTIC TISSUE REMODELING1-3,7

progressive-lung-fibrosis-cycle-diagram
progressive-lung-fibrosis-cycle-diagram

The MOA is based on preclinical data and provided for illustrative purposes only.1

Nintedanib binds intracellularly to key receptors1

FGFR, fibroblast growth factor receptor; ILD, interstitial lung disease; MOA, mechanism of action; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor.

References

  1. OFEV® (nintedanib) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2022.

  2. Hilberg F et al. Cancer Res. 2008;68(12):4774-4782.

  3. Wollin L et al. J Pharmacol Exp Ther. 2014;349(2):209-220.

  4. Wells AU et al. Eur Respir J. 2018;51(5). doi:1183/13993003.00692-2018

  5. Wollin L et al. Eur Respir J. 2019;54(3). doi:10.1183/13993003.00161-2019

  6. Hoffmann-Vold AM et al. EBioMedicine. 2019;50:379-386.

  7. Selman M et al. Ann Intern Med. 2001;134(2):136-151.